401 related articles for article (PubMed ID: 22124940)
21. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
22. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
Mateo J; Heymach JV; Zurita AJ
Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
[TBL] [Abstract][Full Text] [Related]
23. Cases in the Management of GEP-NETs: Combination Regimens.
Braiteh F
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 6):11-3. PubMed ID: 27167993
[No Abstract] [Full Text] [Related]
24. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract.
Strosberg JR; Cheema A; Kvols LK
Cancer Control; 2011 Apr; 18(2):127-37. PubMed ID: 21451455
[TBL] [Abstract][Full Text] [Related]
25. PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.
Briest F; Grabowski P
Theranostics; 2014; 4(4):336-65. PubMed ID: 24578720
[TBL] [Abstract][Full Text] [Related]
26. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Yin F; Wu ZH; Lai JP
World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
[TBL] [Abstract][Full Text] [Related]
27. Cases in the Management of GEP-NETs: The Use of Surgery, an Underutilized Option in the Management of Advanced-Stage NETs.
Boudreaux JP
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 6):7-11. PubMed ID: 27167992
[No Abstract] [Full Text] [Related]
28. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
29. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
Johnson PR
Semin Pediatr Surg; 2014 Apr; 23(2):91-5. PubMed ID: 24931354
[TBL] [Abstract][Full Text] [Related]
30. State of the art and future prospects in the management of neuroendocrine tumors.
Oberg K
Q J Nucl Med; 2000 Mar; 44(1):3-12. PubMed ID: 10932597
[TBL] [Abstract][Full Text] [Related]
31. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.
Massironi S; Conte D; Sciola V; Spampatti MP; Ciafardini C; Valenti L; Rossi RE; Peracchi M
Am J Gastroenterol; 2010 Sep; 105(9):2072-8. PubMed ID: 20372113
[TBL] [Abstract][Full Text] [Related]
32. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
[TBL] [Abstract][Full Text] [Related]
33. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review.
Berardi R; Rinaldi S; Torniai M; Morgese F; Partelli S; Caramanti M; Onofri A; Polenta V; Pagliaretta S; Falconi M; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():264-74. PubMed ID: 26643525
[TBL] [Abstract][Full Text] [Related]
34. [Polish diagnostic and therapeutic guidelines in gastroenteropancreatic neuroendocrine tumors (GEP NET)].
Kos-Kudła B;
Endokrynol Pol; 2006; 57(3):267-72. PubMed ID: 17111342
[No Abstract] [Full Text] [Related]
35. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
Garcia-Carbonero R; Capdevila J; Crespo-Herrero G; Díaz-Pérez JA; Martínez Del Prado MP; Alonso Orduña V; Sevilla-García I; Villabona-Artero C; Beguiristain-Gómez A; Llanos-Muñoz M; Marazuela M; Alvarez-Escola C; Castellano D; Vilar E; Jiménez-Fonseca P; Teulé A; Sastre-Valera J; Benavent-Viñuelas M; Monleon A; Salazar R
Ann Oncol; 2010 Sep; 21(9):1794-1803. PubMed ID: 20139156
[TBL] [Abstract][Full Text] [Related]
36. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Phan AT; Kunz PL; Reidy-Lagunes DL
Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
[TBL] [Abstract][Full Text] [Related]
37. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
Singh S; Law C
Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254
[TBL] [Abstract][Full Text] [Related]
38. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.
Modlin IM; Moss SF; Chung DC; Jensen RT; Snyderwine E
J Natl Cancer Inst; 2008 Sep; 100(18):1282-9. PubMed ID: 18780869
[TBL] [Abstract][Full Text] [Related]
39. Neuroendocrine Tumors.
Basuroy R; Srirajaskanthan R; Ramage JK
Gastroenterol Clin North Am; 2016 Sep; 45(3):487-507. PubMed ID: 27546845
[TBL] [Abstract][Full Text] [Related]
40. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS).
García-Carbonero R; Salazar R; Sevilla I; Isla D
Clin Transl Oncol; 2011 Aug; 13(8):545-51. PubMed ID: 21821488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
